Personalized Approaches to Facial Vitiligo: A Comprehensive Review From Clinical Phenotypes to Novel Therapeutic Strategies

Abstract

Facial vitiligo affects a substantial proportion of patients with vitiligo and is associated with significant psychosocial burden due to its visibility. Facial vitiligo is primarily classified into nonsegmental and segmental subtypes, each with distinct distribution patterns and prognostic features. Nonsegmental vitiligo is further divided into 3 morphological patterns—centrofacial, panfacial, and hairline—each with unique clinical characteristics and treatment responses. The pathogenesis is multifactorial, involving genetic susceptibility, oxidative stress, and autoimmune destruction of melanocytes. Diagnosis is primarily clinical, supported by Wood lamp examination, dermoscopy, and advanced imaging techniques. First-line treatment includes topical calcineurin inhibitors and ruxolitinib, often combined with phototherapy to maximize repigmentation. The 308-nm excimer laser offers targeted delivery of ultraviolet (UV) radiation, minimizing photodamage to uninvolved skin. For progressive disease, systemic corticosteroids are commonly used for stabilization, with methotrexate, cyclosporine, or azathioprine as alternatives. Surgical interventions, particularly micropunch grafting, are effective options for stable, treatment-refractory cases. Emerging therapies, including oral Janus kinase inhibitors and biologics targeting tissue-resident memory T cells, are under investigation with encouraging preliminary results. Lifestyle modifications, including avoidance of mechanical friction, UV protection, and antioxidant-rich dietary patterns, may serve as supportive adjuncts to medical therapy. Recognizing the clinical heterogeneity of facial vitiligo, this review highlights the necessity of individualized treatment strategies based on clinical phenotypes to optimize therapeutic outcomes and improve quality of life.

INTRODUCTION

Vitiligo affects approximately 0.5% to 1% of the global population, with facial involvement present in up to 87% of generalized vitiligo cases¹,²,³. As the face is central to an individual’s identity and social interaction, its involvement in vitiligo has a substantial impact on quality of life⁴. Patients with facial vitiligo experience significantly higher psychosocial burden compared to those without facial involvement⁴,⁵,⁶, with higher rates of diagnosed anxiety (28.8%) and depression (24.5%), with 67.2% reporting at least one mental health problem⁵. Social appearance related anxiety is also particularly pronounced in facial vitiligo, especially when lesions involve the periorbital and perioral regions⁷. Stigma, low self-esteem, and social isolation are frequently reported, with direct negative effects on interpersonal relationships, career prospects, and daily functioning.

The face presents unique therapeutic considerations: while frequently exposed to environmental triggers such as ultraviolet (UV) radiation and friction, it also possesses a high density of hair follicles, serving as a reservoir for melanocyte stem cells. Thus, the face is generally considered a favorable site for repigmentation; however, treatment outcomes remain variable depending on subtypes, disease duration, and individual factors, with some cases requiring surgical intervention. Given the profound psychosocial impact of facial vitiligo and the heterogeneity in treatment response, a personalized approach that integrates patient-specific clinical features with appropriate therapeutic strategies is essential for optimizing outcomes.

CLASSIFICATION AND CLINICAL PHENOTYPES

Nonsegmental vitiligo (NSV)

NSV is the most common form, characterized by bilateral, often symmetric depigmented patches with well-defined borders that may increase in size over time. The lesions typically lack inflammation, and hair depigmentation is usually a late finding. Compared with segmental vitiligo (SV), NSV is associated with more extensive involvement of the body surface area (BSA), a higher incidence of Koebner phenomenon, progressive course with frequent relapses, and increased risk of autoimmune comorbidities such as thyroid disease and alopecia areata¹,⁸.

Three distinct distribution patterns of facial involvement in NSV have been described: centrofacial, panfacial, and hairline vitiligo (Fig. 1)⁹. Centrofacial vitiligo (72.9%) is the most common and representative subtype and occurs across all age groups. This subtype affects the central face, particularly periorificial areas including the periorbital, perinasal, and perioral regions, and it is strongly associated with generalized involvement of other body sites. Panfacial vitiligo (18.0%) is characterized by diffuse depigmentation involving the entire face or predominant involvement of the cheeks and forehead. Notably, it tends to have a later onset and is less frequently associated with extra-facial lesions. Hairline vitiligo (9.1%) presents with lesions localized to the scalp, the hairline from the frontal to the temporal region, and the adjacent forehead. This pattern typically occurs in older patients, often showing a poorer response to conventional phototherapy compared to the others.

Fig. 1. Classification of facial vitiligo. (A) Nonsegmental vitiligo (3 distinct patterns: centrofacial, panfacial, and hairline), segmental vitiligo, and mixed vitiligo. (B) Five distribution patterns of facial segmental vitiligo (F1–F5), with color overlays indicating the typical distribution and extent of involvement for each pattern.

Segmental vitiligo

SV is a distinct subtype characterized by depigmented patches usually occurring in a unilateral, segmental, or band-like distribution⁸,¹⁰,¹¹. It accounts for approximately 5%–30% of all vitiligo cases, with a predilection for the face and trunk¹. SV typically presents during childhood or adolescence, with rapid onset of lesions followed by early stabilization. Early involvement of the follicular melanocyte reservoir is often observed, frequently manifesting as leukotrichia within affected segments. Somatic mosaicism, characterized by postzygotic genetic mutations in melanocytes restricted to the affected segments, has been proposed as the underlying mechanism for this unique distribution pattern.

Based on lesion distribution, facial SV can be further subclassified into 5 patterns: F1-scalp and forehead (SF) involves the scalp and forehead; F2-periorbital (PO) is confined to the periorbital area and often extends laterally; F3-central face (CF) involves the central portion of the face; F4-lip and angular (LA) predominantly involves the perioral area, often arching to the auricular area across the cheek or mandible; and F5-chin and mandible (CM) involves the chin and often extends laterally, downward, or in both directions¹². Since both lesion progression and recurrence typically occur within the same segment, recognizing distribution patterns aids in predicting disease course and planning appropriate management¹¹.

Treatment response is generally less favorable compared to NSV, unless intervention is initiated at a very early stage¹³. Surgical intervention is considered a highly effective option for SV due to its low recurrence rate once stabilization is achieved¹⁴.

Mixed vitiligo

Mixed vitiligo refers to the coexistence of NSV and SV in the same patient, with SV typically preceding the development of NSV. The presence of halo nevi and leukotrichia at onset serves as a clinical predictor for progression to mixed vitiligo, suggesting shared immunological mechanisms between the 2 forms¹⁵.

Undetermined/unclassified vitiligo

Undetermined vitiligo refers to cases that cannot be definitively classified as NSV or SV at initial presentation¹⁶. This category includes focal vitiligo, defined as a small, isolated depigmented macule that does not follow a segmental distribution and does not progress to NSV after 1–2 years of follow-up, as well as isolated mucosal vitiligo confined to a single site.

PATHOPHYSIOLOGY

The pathogenesis of vitiligo is multifactorial, involving genetic susceptibility, environmental triggers, oxidative stress, and immune dysregulation (Fig. 2)¹,¹⁷. Genetic studies have identified susceptibility loci related to immune regulation and melanocyte biology, with tyrosinase and other melanocyte antigens serving as targets for immune attack¹⁸. Environmental triggers, including trauma, chemical exposure, and UV radiation, can precipitate disease onset or exacerbate disease activity in genetically predisposed individuals. The Koebner phenomenon, the development of new lesions at sites of skin injury, is particularly relevant for facial vitiligo²,¹⁹. Inherent alterations in E-cadherin have been identified in patients with vitiligo, which weaken melanocyte adhesion and predispose to melanocyte detachment upon mechanical friction²⁰. This mechanism is consistent with centrofacial vitiligo, in which lesions typically concentrate in areas frequently subjected to repetitive friction⁹.

Fig. 2. Pathogenesis of facial vitiligo. Genetic susceptibility and environmental triggers initiate disease in predisposed individuals. Inherent E-cadherin alterations weaken melanocyte-keratinocyte adhesion, predisposing to melanocyte detachment upon mechanical friction. Oxidative stress induces the release of ROS and DAMPs, such as iHSP70 and HMGB1, which activate innate immunity. Dendritic cells present melanocyte antigens to prime melanocyte-specific cytotoxic CD8⁺ T cells. Activated CD8⁺ T cells produce IFN-γ, which stimulates keratinocytes to secrete CXCL9 and CXCL10, amplifying T cell recruitment through CXCR3 in a positive feedback loop. Impaired Treg cell function fails to suppress autoreactive responses. TRM cells persist in the epidermis, maintained by IL-15 signaling, contributing to disease chronicity and relapse.

ROS: reactive oxygen species, DAMP: damage-associated molecular pattern, iHSP70: inducible heat shock protein 70, HMGB1: high-mobility group box 1 protein, IFN: interferon, CXCL: C-X-C motif chemokine ligand, CXCR: C-X-C motif chemokine receptor, Treg: regulatory T, TRM: tissue-resident memory T, IL: interleukin, UV: ultraviolet, DC: dendritic cell, NK: natural killer.

Oxidative stress in melanocytes, triggered by environmental factors such as UV exposure, chemical exposure, or infection, leads to the release of damage-associated molecular patterns and reactive oxygen species²¹—a mechanism particularly relevant in panfacial vitiligo, which preferentially affects sun-exposed areas⁹. These signals activate the innate immune system, including dendritic cells and natural killer cells, promoting antigen presentation, and bridging to the adaptive immune response²². The adaptive response is characterized by activation of melanocyte-specific cytotoxic CD8⁺ T cells, which produce interferon (IFN)-γ and drive targeted destruction of melanocytes²³. IFN-γ also induces the secretion of chemokines such as C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10 from keratinocytes, amplifying T cell recruitment through a positive feedback loop²⁴. Impaired suppressive function of regulatory T cells and persistence of tissue-resident memory T (TRM) cells further contribute to disease chronicity and relapse²⁵.

In SV, somatic mosaicism is proposed as the underlying mechanism. Postzygotic mutations occurring during melanoblast migration generate a segmentally distributed population of genetically altered melanocytes. These mosaic melanocytes are thought to trigger a localized cytotoxic CD8⁺ T cell response, and disease activity typically stabilizes once the susceptible melanocytes are eliminated.

DIAGNOSIS

The diagnosis of facial vitiligo is primarily clinical, supported by several adjunctive modalities. Wood lamp examination, using UV-A light at approximately 365 nm, enhances contrast between normal and vitiligo skin, particularly useful in lighter skin types or when lesions are subtle, enabling detection of subclinical lesions and accurate delineation of disease extent²⁶.

UV and cross-polarized photography allow more detailed visualization of vitiligo lesions²⁶,²⁷. Recently, 3-dimensional imaging and automated algorithmic methods have been developed for objective and quantitative assessment, offering more reliable and reproducible measurements of facial vitiligo²⁸.

Dermoscopy is valuable for evaluating disease activity and distinguishing vitiligo from other hypopigmented disorders. Characteristic features include the starburst pattern, micro-Koebnerization, confetti-like depigmentation, trichrome pattern, and comet-tail appearance. Findings such as micro-Koebnerization and ill-defined margins suggest active disease, while well-defined borders and perifollicular repigmentation are associated with disease stability²⁹,³⁰. Furthermore, dermoscopy enables more precise identification of leukotrichia, which may serve as a predictor of response to excimer laser therapy³¹.

The common differential diagnosis of facial vitiligo includes nevus depigmentosus, pityriasis alba, pityriasis versicolor, postinflammatory hypopigmentation, chemical leukoderma, idiopathic guttate hypomelanosis, and piebaldism (Table 1). These conditions can be differentiated based on clinical features such as age of onset, lesion morphology, border characteristics, and relevant history. Skin biopsy is rarely required but may be considered in diagnostically challenging cases or to exclude mimickers⁸.

Table 1. Differential diagnosis of facial vitiligo.

Disease	Age of onset	Pathophysiology	Key features & differential points
Nonsegmental vitiligo	All age groups; panfacial often later onset; hairline typically older patients	Complex interplay of genetic susceptibility, oxidative stress, and autoimmune destruction of melanocytes by cytotoxic T cells	Acquired; often progressive; bilateral, symmetric distribution; lacks inflammation/scaling; complete absence of melanocytes; enhanced under Wood lamp; frequently associated with acral or other body site involvement; 3 facial patterns: centrofacial (periorificial), panfacial (diffuse), and hairline
Segmental vitiligo	Childhood or adolescence	Somatic mosaicism (postzygotic mutations) in melanocytes triggering localized cytotoxic T cell response	Unilateral, segmental, or band-like distribution; rapid onset followed by early stabilization; early leukotrichia is common
Nevus depigmentosus	Congenital or noticed within the first 3 years of life	Functional defect in melanogenesis (reduced melanin synthesis/transfer) due to somatic mosaicism; melanocytes present	Congenital; may be first noticed in early infancy; stable and non-progressive; grows proportionately with body; hypopigmented (off-white/cream) macules; melanocytes present
Pityriasis alba	Children and adolescents	Low-grade eczematous dermatitis; post-inflammatory hypopigmentation	Ill-defined, round/oval hypopigmented (not chalk-white) patches with fine branny scale; predominantly on the face; associated with atopic diathesis and xerosis; resolves spontaneously over months to years
Pityriasis versicolor	Young adults; facial involvement more common in children	Superficial Malassezia infection producing azelaic acid, which inhibits tyrosinase in melanocytes	Hypopigmented patches with fine scale and less sharp borders; trunk, neck, and proximal extremities; fungal origin (KOH: spaghetti and meatballs); yellow-green fluorescence under Wood lamp
Postinflammatory hypopigmentation	Any age	Decreased melanin production, impaired melanosome transfer to keratinocytes, and/or melanocyte loss	Hypopigmented macules/patches localized to sites of prior inflammation or injury; history of preceding dermatitis or trauma; typically resolves spontaneously
Chemical leukoderma	Any age	Toxic destruction of melanocytes by phenol/catechol derivatives	Well-demarcated depigmented macules/patches; characteristic “confetti” macules; distribution follows contact area; history of chemical (phenol/catechol) exposure; can spread to remote sites
Idiopathic guttate hypomelanosis	Older adults	Cutaneous senescence and cumulative photoaging; degenerative focal reduction of melanocytes	Small (2–5 mm), porcelain-white, well-demarcated discrete macules; sun-exposed areas; does not coalesce or enlarge; associated with aging and cumulative sun damage; hair pigment retained
Piebaldism	Congenital	Autosomal dominant disorder; KIT mutation causing failure of melanocyte migration from the neural crest during embryogenesis; absence of melanocytes in affected areas	Congenital; stable throughout life; depigmented patches on ventral midline; pathognomonic “white forelock” (poliosis) in 90%

CLINICAL ASSESSMENT

The primary clinical assessment tool for facial vitiligo is the Facial Vitiligo Area Scoring Index (F-VASI). Vitiligo Area Scoring Index (VASI) quantifies the proportion of affected surface area and the degree of depigmentation within each lesion, using the Hand Unit as a reference, where one Hand Unit corresponds to 1% of BSA³². Since facial lesions are often smaller than one hand, the Fingertip Unit (FTU), defined as the distal phalanx of the index finger, may be used alternatively. Thirty-two FTUs are equivalent to one Hand Unit and can be integrated into the total VASI³³. Clinically meaningful repigmentation is commonly defined as ≥50%, ≥75%, or ≥90% reduction in F-VASI, depending on the study context.

MEDICAL MANAGEMENT

Topical therapies

Topical calcineurin inhibitors, including tacrolimus (0.03% and 0.1%) and pimecrolimus (1%), are recommended as first-line therapy for facial vitiligo due to their favorable safety profile and lack of steroid-induced atrophy, which is particularly relevant given the thin nature of facial skin (Table 2)³⁴,³⁵. Topical calcineurin inhibitor monotherapy has been reported to achieve ≥25% repigmentation in approximately 55% of patients after a median of 3 months, with higher response rates in face/neck lesions (≥25% repigmentation in 73%)³⁶, further enhanced when combined with phototherapy³⁷.

Table 2. Summary of treatment for facial vitiligo.

Treatment		Mechanism of action	Key characteristics & major findings
1. Topical agents
	Topical calcineurin inhibitors	Inhibits cytotoxic T cell activation via calcineurin blockade; promotes melanocyte migration, proliferation, and melanogenesis	First-line treatment for face/neck; better safety profile than corticosteroids; twice-daily application recommended
			Monotherapy achieved F-VASI 25 in 73.1% and F-VASI 75 in 35.4% for facial/neck lesions
	Topical corticosteroids	Immune suppression; anti-inflammatory effects	First-line for localized vitiligo; risks include skin atrophy, telangiectasia, glaucoma and cataract (periocular); intermittent regimen (e.g., 2 wk on/off) advised
	Topical ruxolitinib 1.5% cream	Selective JAK1 and JAK2 inhibition	First treatment approved by FDA/EMA for repigmentation in patients aged ≥12 yr; twice-daily application; side effects include application site acne and pruritus
			F-VASI 75 achieved in 31% at 24 wk and 50.3% at 52 wk
2. Systemic therapy
	Systemic corticosteroids	Systemic immune suppression and stabilization to arrest rapidly progressive disease	OMP regimen (e.g., betamethasone/dexamethasone 5 mg or methylprednisolone 0.5 mg/kg administered on 2 consecutive days per week) for 3–6 mo; monitoring for weight gain, acne, and growth retardation required
	Methotrexate	Systemic immunomodulatory antimetabolite inhibiting folate-dependent pathways	Used as an alternative for unstable vitiligo at 10 to 12.5 mg weekly; comparable efficacy to OMP in disease stabilization
	Cyclosporine	Calcineurin inhibition leading to suppression of T cell–mediated immune activity	Used as an alternative for unstable vitiligo; effective for stabilization with faster onset than OMP therapy
	Azathioprine	Purine synthesis inhibition resulting in systemic immunosuppression	Used as an alternative for unstable vitiligo when first-line options are ineffective; limited strong evidence for routine use
3. Phototherapy
	NB-UVB phototherapy	Immune modulation through induction of T cell apoptosis and stimulates melanocyte stem cell differentiation and migration	Gold standard for vitiligo involving large body surface area; administered 2–3 times weekly for at least 6 mo
			F-VASI 75 achieved in 44.2% on face and neck lesions
	The 308-nm excimer laser/light	Targeted UVB phototherapy inducing localized T cell apoptosis and melanocyte proliferation and migration	Preferred for limited/localized vitiligo (≤10% BSA); minimizes photodamage to normal skin; faster and more extensive repigmentation than NB-UVB for localized areas
	The 311-nm titanium:sapphire laser	Targeted phototherapy delivering monochromatic 311-nm light	Comparable efficacy and safety to excimer laser for localized vitiligo, especially facial lesions
4. Surgical intervention
	Suction blister epidermal grafting	Transfer of autologous epidermal sheets/melanocyte-bearing epidermis to recipient sites	Excellent cosmetic results with minimal donor site scarring; requires preparation time for blister induction
			90% repigmentation achieved in 61.7% of patients
	Punch grafting	Transfer of small (punch grafting, 1–2 mm; micropunch grafting, 0.5–0.8 mm) tissue punches	Simple, cost-effective, feasible in outpatient settings; motorized devices enable faster procedures
			90% repigmentation achieved in 45.8% of patients
	Non-cultured epidermal cell suspension	Enzymatic separation of donor cells and transplantation of melanocyte-keratinocyte suspension	Most commonly performed cellular technique; outcomes are surgeon-dependent; processing is time-consuming (3–4 hr); enables treatment of large areas with small donor tissue (1:10 ratio)
			90% repigmentation achieved in 47.5% of patients
5. Maintenance therapy
	Topical calcineurin inhibitors	Local immunomodulation and stabilization of repigmented skin	Recommended proactive treatment (twice-weekly application) to prevent recurrence and maintenance of pigmentation
			Maintenance of pigmentation in 96% of facial/neck lesions in tacrolimus group vs. 60% with placebo
	Maintenance phototherapy	Continued low-dose UV exposure to maintain melanocyte activity and modulate local immune responses	Tapering regimens suggested after complete repigmentation (twice-weekly → weekly → every other week over 4 mo)
			Monthly half–maximum-dose phototherapy for 12 mo showed reduced recurrence compared with placebo (30.1% vs. 40.5%)
6. Emerging therapies
	Ritlecitinib	Oral JAK3 and TEC family kinase inhibitor	Phase 2b trial showed mean F-VASI improvement of −18.5% to −21.2% at 24 wk with the 50 mg daily dose, compared with 2.1% in the placebo group; evaluated in adult active nonsegmental vitiligo
			Phase 3 study for vitiligo is ongoing (NCT05583526)
	Povorcitinib	Oral selective JAK1 inhibitor	Phase 2 trial showed F-VASI improvement of 27.7% to 36.4% at 24 wk at daily doses of 15, 45, and 75 mg; evaluated in adult nonsegmental vitiligo
			Phase 3 studies for vitiligo are ongoing (NCT06113445, NCT06113471)
	Upadacitinib	Oral selective JAK1 inhibitor	Phase 2 trial showed significant least-squares mean differences in F-VASI improvement of −21.27% and −19.60%, respectively, compared with placebo at 24 wk at daily doses of 11 mg and 22 mg; evaluated in adult nonsegmental vitiligo
			Phase 3 study for vitiligo is ongoing (NCT06118411)
	AMG 714	Anti-IL-15 monoclonal antibody	Currently in a phase 2 clinical trial (NCT04338581)
	Anifrolumab	Monoclonal antibody against the type I interferon receptor	Currently in a phase 2 clinical trial for nonsegmental progressive vitiligo (NCT05917561)

F-VASI: Facial Vitiligo Area Scoring Index, JAK: Janus kinase, FDA: Food and Drug Administration, EMA: European Medicines Agency, OMP: oral mini-pulse, NB-UVB: narrowband ultraviolet B, BSA: body surface area, UV: ultraviolet, TEC: tyrosine kinase expressed in hepatocellular carcinoma, IL: interleukin.

Topical corticosteroids remain effective, especially potent agents (e.g., mometasone furoate, fluticasone propionate); however, their use on the face is generally limited to short-term or intermittent regimens because of the risk of cutaneous adverse effects, including skin atrophy, telangiectasia, and striae, as well as ocular complications such as glaucoma and cataracts with periocular applications¹,³⁴.

Topical ruxolitinib 1.5% cream is a US Food and Drug Administration-approved Janus kinase 1/2 (JAK1/2) inhibitor for the treatment of NSV in patients aged 12 years and older. In the 2 phase 3 randomized controlled trials (RCTs; TRuE-V1 and TRuE-V2), twice-daily application of ruxolitinib 1.5% cream resulted in ≥75% facial repigmentation in approximately 31% of patients at week 24³⁸. Continued treatment was associated with further improvement, with 50.3% of patients achieving ≥75% facial repigmentation at week 52³⁸,³⁹. Reported adverse events were generally mild, most commonly including application-site acne and pruritus. Repigmentation outcomes can be further enhanced when ruxolitinib is combined with phototherapy⁴⁰.

Systemic therapies

Systemic corticosteroids, particularly oral mini-pulse (OMP) therapy, are indicated for rapidly progressive vitiligo to arrest disease activity. OMP regimens typically involve dexamethasone at a dose of 5 mg or methylprednisolone at a dose of 0.5 mg/kg administered on 2 consecutive days per week for 3 to 6 months⁴¹,⁴². Systemic corticosteroids are recommended in combination with phototherapy⁴³. Adverse effects, including weight gain, sleep disturbance, acne, menstrual irregularities, hypertrichosis, and growth suppression in children, should be considered, but are typically minimized with intermittent, low-dose treatment⁴⁴.

Alternative systemic immunosuppressants, including methotrexate, cyclosporine, and azathioprine, are considered when corticosteroids are contraindicated or ineffective¹,³⁴. Methotrexate (10 to 12.5 mg/week) has demonstrated comparable efficacy to corticosteroid OMP therapy for disease stabilization⁴⁵. Cyclosporine (3 mg/kg/day) has been reported to be effective for disease stabilization, with more rapid onset of action compared with OMP therapy⁴⁶.

PHOTOTHERAPY

Narrowband ultraviolet B (NB-UVB) phototherapy

UV-based phototherapy has long been a mainstay of the treatment of vitiligo. NB-UVB, with a sharp emission peak around 311 nm, is the most widely used phototherapy for extensive lesions and is regarded as a safe and effective option for inducing repigmentation and stabilizing disease activity. Meta-analyses indicate that after at least 6 months of NB-UVB treatment, approximately 44% of patients achieve ≥75% facial repigmentation, a response rate higher than that observed at other body sites⁴⁷.

Laser therapy

The 308-nm excimer laser/light is a well-established targeted phototherapy modality for localized facial vitiligo, allowing precise irradiation of lesional skin while sparing adjacent normal tissue. This selectivity reduces unwanted tanning and enhances cosmetic outcomes⁴⁸,⁴⁹. Previous studies have shown that 308-nm excimer laser/light tends to induce faster and higher rates of repigmentation than NB-UVB, especially in localized vitiligo⁵⁰. Cyclic on-off schedules and suberythemic dosing regimens further optimize efficacy while minimizing adverse effects⁵¹,⁵².

The 311-nm titanium:sapphire laser has also been introduced as a targeted phototherapeutic modality, demonstrating comparable efficacy and safety to the 308-nm excimer laser for localized vitiligo, especially for facial lesions⁵³,⁵⁴.

TREATMENT RESPONSE

Facial vitiligo generally shows more favorable treatment responses compared to vitiligo affecting other body sites³⁶,⁴⁷. The face possesses a high density of hair follicles, which serve as reservoirs of melanocyte stem cells located within the bulge region. This bulge area is a protected niche that allows melanocyte precursors to survive immune-mediated destruction and later migrate to repopulate the epidermis during repigmentation, particularly when stimulated by treatments such as NB-UVB phototherapy¹,⁵⁵,⁵⁶. The presence of leukotrichia suggests depletion of this follicular reservoir and is associated with a poorer response to phototherapy, often necessitating surgical intervention⁵⁷. Meanwhile, the perioral region and the vermilion of the lips have limited or absent hair follicles, resulting in resistance to medical therapy⁵⁸.

SURGICAL INTERVENTION

Surgical intervention is indicated for stable vitiligo that has failed to respond to conventional phototherapy, particularly in patients with SV or localized NSV. Stability should be confirmed for at least 12 months, with no evidence of new or enlarging lesions¹⁴.

Surgical techniques are broadly categorized into tissue and cellular grafting. Tissue grafting involves the transfer of melanocyte-bearing skin from a donor site to depigmented recipient areas. Suction blister epidermal grafting minimizes donor site scarring by harvesting the epidermis through subepidermal blister formation under sustained low-pressure suction. However, the technique requires considerable preparation time for blister induction¹⁴,⁵⁹. Punch grafting (1–2 mm) is a simple, cost-effective, and feasible approach that can be performed in the outpatient setting. However, it is time-consuming and frequently results in a cobblestoning appearance at both donor and recipient sites. The introduction of motorized micropunch devices that harvest smaller grafts (0.5–0.8 mm) has substantially reduced procedural time and the incidence of cobblestoning, yielding improved cosmetic outcomes (Fig. 3)⁶⁰,⁶¹.

Fig. 3. Micropunch grafting for facial vitiligo refractory to conventional phototherapy. A 22-year-old woman with segmental vitiligo along the right periauricular and mandibular areas underwent 2 sessions of micropunch grafting, achieving complete repigmentation after 4 months of postoperative excimer laser therapy.

Non-cultured epidermal cell suspension, the most widely performed cellular grafting technique, enables treatment of larger areas (donor-to-recipient ratio up to 1:10)⁶². However, cell processing is time-consuming, and outcomes are highly dependent on the surgeon’s experience and technique¹⁴. These approaches have undergone technical refinements to improve repigmentation rates and cosmetic outcomes⁶³,⁶⁴.

Postoperative phototherapy is commonly employed to promote melanocyte survival and spreading by creating a favorable microenvironment for transplanted melanocytes¹⁴.

MAINTENANCE THERAPY

Relapse rates after successful repigmentation are substantial, with approximately 40% of lesions recurring within the first year after stopping treatment⁶⁵. Therefore, maintenance therapy plays a crucial role in maintaining achieved repigmentation, particularly for facial lesions, where recurrence may have a substantial psychosocial impact.

Twice-weekly application of topical calcineurin inhibitors, such as tacrolimus 0.1% ointment, is recommended for maintenance therapy. An RCT demonstrated that this maintenance regimen significantly reduced recurrence over 24 weeks, with recurrence rates of 9.7% in treated lesions and 40% in placebo-treated lesions⁶⁶. Notably, the effect appeared to be more pronounced for facial and neck lesions, with 96% maintaining pigmentation in the tacrolimus group compared with 60% in the placebo group, supporting its particular utility in facial vitiligo where treatment response is typically most favorable.

Maintenance phototherapy with NB-UVB or 308-nm excimer laser has also been investigated. A multicenter RCT using monthly phototherapy at half the maximum dose for 12 months showed a trend toward reduced recurrence (30.1% vs. 40.5%), although this difference was not statistically significant⁶⁷. The Vitiligo Working Group recommends a tapering regimen after complete repigmentation: twice-weekly sessions for the first month, weekly for the second month, and every other week for the third and fourth months before discontinuation⁶⁸.

EMERGING THERAPIES

Systemic JAK inhibitors

Oral JAK inhibitors, including ritlecitinib, povorcitinib, and upadacitinib, have shown promising efficacy for facial vitiligo in recent phase 2 clinical trials. Ritlecitinib (JAK3/tyrosine kinase expressed in hepatocellular carcinoma inhibitor) demonstrated a mean percentage change from baseline in F-VASI ranging from −18.5% to −21.2% at 24 weeks with the 50 mg daily dose (with or without a 4-week loading dose), compared with 2.1% in the placebo group⁶⁹. Povorcitinib (JAK1 inhibitor) administered at daily doses of 15, 45, or 75 mg resulted in mean F-VASI improvements of 27.7% to 36.4% at 24 weeks, whereas placebo-treated patients showed a mean change of 5.1%⁷⁰. Upadacitinib (JAK1 inhibitor) administered at daily doses of 11 mg and 22 mg yielded least-squares mean differences in F-VASI improvement of −21.27% and −19.60%, respectively, compared with placebo at 24 weeks⁷¹. Across these trials, safety profiles were generally favorable, with the most commonly reported adverse events including mild infections, headache, and acne.

Novel biologics

Anti-interleukin (IL)-15 antibodies targeting TRM cells have demonstrated durable repigmentation and depletion of TRM cells from lesional skin in preclinical mouse models⁷²,⁷³. These agents may offer the potential for long-term remission with minimal systemic immunosuppression, and a phase 2 clinical trial (NCT04338581) evaluating AMG 714, an anti-IL-15 antibody, in adults with vitiligo is currently underway⁷⁴. In addition, the type I IFN pathway is emerging as another therapeutic target in vitiligo; anifrolumab, a monoclonal antibody against the type I IFN receptor, is being evaluated in an ongoing phase 2 proof-of-concept clinical trial (NCT05917561)⁷⁴,⁷⁵.

SPECIAL CONSIDERATIONS

Pediatric management

Management of pediatric facial vitiligo prioritizes the use of topical calcineurin inhibitors as first-line therapy because of their favorable safety profile⁷⁶. Topical corticosteroids can be considered as second-line agents for facial vitiligo and are used in short-term or intermittent regimens³⁴. Topical ruxolitinib 1.5% cream is approved for use in patients aged 12 years and older¹. Phototherapy modalities, including NB-UVB and 308-nm excimer laser, are effective and well tolerated in pediatric populations³⁵,⁴⁹.

Management of hyperpigmentation during phototherapy

Hyperpigmentation is a frequent concern during phototherapy for facial vitiligo, as excessive darkening of perilesional or repigmented skin can negatively impact patient satisfaction and quality of life. A range of therapeutic strategies has been investigated to mitigate this complication while preserving therapeutic efficacy and optimizing cosmetic outcomes.

Suberythemic dosing of 308-nm excimer laser, defined as half the conventional minimal erythema dose, has demonstrated repigmentation rates comparable to standard protocols, with significantly reduced hyperpigmentation when combined with topical tacrolimus⁵¹. Concomitant application of topical tretinoin 0.05% cream during NB-UVB phototherapy has been shown to effectively prevent hyperpigmentation without compromising therapeutic response, although treatment-related irritation may require dilution with a moisturizer⁷⁷.

For patients with concurrent melasma, oral tranexamic acid has been demonstrated to improve melasma without interfering with vitiligo treatment⁷⁸. Polypodium leucotomos extract, an oral antioxidant supplement, has exhibited efficacy in treating melasma⁷⁹ and in enhancing vitiligo repigmentation during NB-UVB phototherapy⁸⁰, suggesting a potential benefit for managing phototherapy-associated hyperpigmentation. Furthermore, a topical serum containing vitamins C and E, and ferulic acid has shown preliminary efficacy in the management of post-excimer laser hyperpigmentation⁸¹.

Notably, hydroquinone, a widely used depigmenting agent, should be avoided in vitiligo patients due to its melanocytotoxic properties and documented potential to induce disease exacerbation or chemical leukoderma⁸².

Periocular safety during phototherapy

For the treatment of topical calcineurin inhibitors are preferred over topical corticosteroids owing to their lower risk of skin atrophy, telangiectasia, and steroid-induced glaucoma or cataracts. During NB-UVB phototherapy, protective eyewear is generally recommended to prevent both acute and chronic ocular injury⁸³. However, for eyelid lesions, treatment can be safely performed with the eyes closed, as the Bell phenomenon provides inherent ocular protection through reflex upward rotation of the eyeball upon lid closure⁸⁴.

Psychosocial support

Given the significant psychosocial burden associated with facial vitiligo, psychological support is an integral component of an individualized management plan. Clinicians should proactively assess patients for signs of anxiety or depression and refer them to mental health professionals or support groups when indicated. Combining medical treatment with psychological support can improve adherence and overall quality of life.

Camouflage

Camouflage can play a supportive role in improving the quality of life for patients with facial vitiligo. Options include medical tattooing, corrective makeup, and temporary camouflage agents, which can be tailored to patient preferences and lesion characteristics⁸⁵. This approach has been associated with improved psychological well-being and enhanced self-esteem⁸⁶,⁸⁷.

Depigmentation

Depigmentation therapy is reserved for patients with vitiligo universalis or extensive, treatment-refractory facial involvement in whom repigmentation is not feasible. Available modalities include topical monobenzyl ether of hydroquinone (20%), trichloroacetic acid peels (25%–50%), and laser therapies (e.g., Q-switched ruby, alexandrite, or Nd:YAG lasers)⁸⁸.

Lifestyle and dietary modifications

Given the chronic course and substantial propensity for relapse, the management of facial vitiligo necessitates an integrative approach that incorporates lifestyle and dietary modifications. Minimizing mechanical stress is fundamental to prevent the Koebner phenomenon; therefore, patients should be advised to avoid habitual rubbing or friction around the eyes, nose, and mouth, to use gentle techniques when removing makeup, and to adopt cautious shaving practices¹⁹. UV protection is essential to prevent sunburn and reduce reactive oxygen species generation, especially in patients with panfacial vitiligo; broad-spectrum sunscreens (SPF ≥30) should be applied daily, and physical barriers such as hats and masks are recommended for additional protection⁸⁹. Patients with hairline vitiligo who have a history suggestive of hair dye-related disease exacerbation should be advised to avoid using permanent hair dye products⁹⁰.

Patients should also be counseled to avoid smoking and excessive alcohol consumption, as these behaviors are associated with increased risk and severity of vitiligo⁸⁹. Antioxidant-rich foods (e.g., apples, green tea, Indian gooseberry) may mitigate oxidative stress⁸⁹,⁹¹,⁹², and supplementation with vitamin E, B12, copper, and zinc has been proposed as a potential adjunctive strategy⁸⁹,⁹³. Sleep disturbances and psychological stress are common in vitiligo and should be addressed as part of a holistic management approach⁹⁴.

CONCLUSIONS

Facial vitiligo requires special clinical attention given its substantial psychosocial impact and impairment in quality of life. Accurate subtype classification is fundamental, as clinical course and treatment response vary considerably among different phenotypes. Owing to its favorable repigmentation potential, facial involvement justifies intensive treatment strategies irrespective of disease extent at other body sites. A personalized, multimodal approach, incorporating phenotype-specific management strategies and psychological support, remains the cornerstone of successful long-term outcomes.